Decision With Precision

Promoting Personalised Medicine By Bringing Functional Proteomics To Pathology

QF-Pro®, a transformative platform that unveils post-translational modifications and protein-protein interactions in pathology samples

FASTBASE´s companion diagnostics platform, QF-Pro®, quantifies protein-protein interactions and protein post-translational modifications in single cell and fixed tissue samples. By design the platform has built in specificity and preserves the morphological integrity and cellular heterogeneity of the tissue. It can be exploited for pharmacodynamics, precision diagnostics and prognostics designed to impact clinical practice.

Learn More About QF-Pro®

Powerful Biomarkers for better Treatment Stratification

Protein complexes and protein post translational modifications (PTM) characterise functional states of proteins pertinent to disease. In the microenvironment of a tissue, assessments of these attributes provide markers of disease that are more relevant than simple expression levels of proteins. The QF-Pro® platform can deliver on this information, providing a better route to treatment decisions in cancer, inflammation and immune disorders.

Learn More About our Biomarkers

Meet the Fastbase Team

Our team is composed of industrial experts and world-class scientists with common values and a strong shared vision: better diagnostics for better patient outcomes. Our depth and breadth of expertise in advanced molecular diagnostics, along with the considerable academic and research expertise of our founders and our exclusive proprietary technologies, positions us at the forefront of precision pathology.

Learn More About our Team

News

Tumor Biomarker

Tumor biomarkers. What are they and what are they for?

| News | 56 Comments
Surely you have been told more than once to undergo a blood test in order to see how your biomarkers are. If you are a male over 45 years of…
QF-Pro® diagnostic platform

Our QF-Pro® diagnostic platform successfully passes the first trials for lung cancer validation

| News | 7 Comments
Anti-tumor treatment with immunotherapy has become a reality for many patients and currently, its use is being widespread to more and more cancer types. Among all immunotherapy strategies, immune checkpoint…

The French translational oncology accelerator, MATWIN, awards the QF-Pro(PD-1/PD-L1) assay as ‘Best Predictive Test’

| News | 4.016 Comments
The panel of 20 members, including 13 leading global industrial decision makers in oncology R&D, shortlisted 10 projects based on their promising medical findings and potential for industrial development. Three…

FASTBASE opens a funding round

| News | 5.264 Comments
In keeping with its growth strategy, FASTBASE has recently opened a 600K€ round of financing to incorporate new partners into the company. The round will be made through the Capital…

Careers

When joining us, you have a unique opportunity to be the one. You are becoming part of the team that’s shaping the next innovation platform for diagnostics, right here and now. You will join a strong, values-driven organization focused on our people and in advancing cutting-edge science.

Join The Fastbase Team

Contact Us.

Astondo bidea, Kabi 612
Scientific and Technology Park of Bizkaia
48160 Derio, Spain